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Available online 17 September 2010Nowadays statins are a cornerstone in perioperative and
long-term cardiovascular risk reduction in vascular surgery
patients. As has been strongly advocated by the recent
European Society of Cardiology guidelines for perioperative
management statins should be prescribed to virtually all
patients undergoing vascular surgery.1 This recommenda-
tion has subsequently been reinforced by the results of the
DECREASE III trial.2 The results of this placebo-controlled
randomized trial showed a two-fold reduction in perioper-
ative cardiac complications in patients on statins. Though
not powered for subgroup analyses there seemed to be no
significant difference of effect in open or endovascular
treated patients.
The study by Moulakakis focusses on a different, less
well understood, potential beneficial effect of statins in
vascular surgery patients.3 In this retrospective study
patients on statins experienced a significantly lower rate of
renal function deterioration compared to patients not on
statins when undergoing endovascular abdominal aneurysm
repair requiring suprarenal fixation.
Data on the potential renal protective effect of statins in
patients undergoing EVAR are scarce. However in open
vascular surgery large cohort studies have found similar
results. Welten et al. studied 1944 patients undergoing open
vascular surgery.4 In this population acute kidney injury,
defined as >10% decrease in creatinine clearance, occurred
in 664 (34%) patients within 2 days after surgery. Of the 664DOI of original article: 10.1016/j.ejvs.2010.05.006.
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doi:10.1016/j.ejvs.2010.08.005patients with acute kidney injury, 313 patients (47%) had
acomplete recoveryof kidney functionat day3after surgery.
Interestingly, in this study statin use was not associated with
prevention of kidney injury. However, if kidney injury
occurred, patients on statins were 2-fold more likely to have
a complete recovery in kidney function within 3 days after
surgery compared to those not on statins. In another study
only patients with suprarenal aortic cross-clamping were
included.5 Seventy-seven patients with normal preoperative
renal function requiring suprarenal aortic cross clamping
were studied. Creatinine levels were obtained before
surgery and on days 1, 2, 3, 7, and 30 after surgery. An
analysis-of-variance model for repeated measurements was
applied to compare creatinine levels between statin users
and nonusers, with adjustment for clamping time and blood
loss. Postoperative creatinine levels during the 30 days after
surgery were significantly lower in statin users than in non-
users. Postoperative hemodialysis was required (tempo-
rarily) in 7 patients (9.1%), all statin nonusers. The
mechanism of this beneficial effect of statins in open
vascular surgery remains speculative due to the multifacto-
rial causes of postoperative kidney function impairment. As
already stated by Moulakakis there are several so-called
“pleiotropic” effects of statins that might be relevant for
postoperative kidney injury prevention such as improved
endothelial function, modulated inflammatory response,
decreased oxidative stress, and maintenance of plaque
stability. These effects have been found in animal studies but
are more difficult to assess in the clinical setting.
As stipulated by Moulakakis et al. renal dysfunction in
EVAR may also be induced by the potential nephrotoxicity
of the relatively high dose of administered contrast
medium during endovascular procedures. In a large cohort
study by Khanal et al. 29,409 patients undergoingd by Elsevier Ltd. All rights reserved.
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procedure and peak postprocedure serum creatinine was
measured.6 When compared with patients who did not
receive preprocedure statins, patients on preprocedure
statins had a lower incidence of contrast induced
nephropathy (4.4 vs. 5.9%, P < 0.0001) and nephropathy
requiring dialysis (0.3 vs. 0.5, P Z 0.03). However, in
a recent randomized trial by Toso et al. of 304 patients
with impaired preprocedural renal function short-term, i.e.
2 days pre to 2 days post-intervention, atorvastatin 80 mg
on top of intravenous saline hydration and oral N-ace-
tylcysteine 1200 mg 2 times/day did not result in
a decrease in contrast-induced nephropathy.7 These results
were a confirmation of the PROMISS trial which also showed
no beneficial effect of short term simvastatin 40 mg
administration for the prevention of contrast induced
nephropathy.8 However, it should be noted that the patient
population of the Moulakakis trial was substantially
different in terms of timing of statin therapy, dosing of
statins and preprocedural renal function.
The mechanism of a possible kidney protective effect of
statins remains speculative. In daily clinical practice this
should not hamper the liberal use of statins in patients pre-
senting for abdominal aortic aneurysm repair. Even if the
level of evidence for the use of statins for the prevention of
kidney injury is weak, the overwhelming beneficial effect of
perioperative and long-term statin use for cardiovascular risk
reduction makes statin use imperative in this patient pop-
ulation. Therefore the question whether statins also have
renoprotective effects will remain speculative as placebo-
controlled trialswill not beethically justifiable in this patient
population. Studies on statins and renoprotective effects in
AAA patients should focus on the question whether type of
statins, dosing of statins and timing of statin therapy initia-
tion are of importance for the prevention of kidney injury in
patients undergoing vascular surgery.References
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